1802518-92-8
Chemical Structure
Minzasolmin
Synonym(s): UCB0599;(R)-NPT200-11
- CAS No.: 1802518-92-8
- Formula:C23H31N5OS
- Molecular Weight:425.59
IUPAC Name: (R)-N-(1-(1H-indol-3-yl)hexan-2-yl)-2-(4-methylpiperazin-1-yl)thiazole-5-carboxamide
InChIKey: GDFWCSZNQVAQGR-GOSISDBHSA-N
SMILES: O=C(C1=CN=C(N2CCN(CC2)C)S1)N[C@H](CCCC)CC3=CNC4=CC=CC=C34
Biological Activity: Minzasolmin (UCB0599; (R)-NPT200-11) is an orally active, blood-brain-permeable α-synuclein (α-Syn) inhibitor that selectively binds to α-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of α-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and α-Syn-related pathological deposition in transgenic mouse models[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Minzasolmin | 98.60% | Minzasolmin (UCB0599; (R)-NPT200-11) is an orally active, blood-brain-permeable α-synuclein (α-Syn) inhibitor that selectively binds to α-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of α-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and α-Syn-related pathological deposition in transgenic mouse models. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Steiner MA. Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease. NPJ Parkinsons Dis. 2024 Mar 14;10(1):59. [Content Brief]
- [2]. Baggett, et al. Novel Approaches Targeting in α-Synuclein for Parkinson's Disease: Current Progress and Future Directions for the Disease-Modifying Therapies. Brain Disorders (2024): 100163.
Keywords
